Micra was first approved by the FDA in 2016, and now over 100,000 patients globally are potentially benefiting from Micra technology.1 Ongoing physician training and clinical research remains a cornerstone for Micra. Currently, more than 17,000 Micra patients are being followed in global clinical trials.
"Micra has an outstanding safety profile, quicker post-procedure recovery time, and excellent long-term longevity. For the right patient, it is aesthetically very compelling, being truly out of sight and out of mind."
"From the very beginning I knew that leadless pacing was a technology that would come to stay. With Micra AV, we implant leadless pacemakers for more indications — and that is really good news for our patients!"
"Because the physique of Japanese patients is often small, they appreciate that this pacemaker is miniaturized and totally implanted inside the heart."
"My patients say that they forget they have a pacemaker and feel free from daily worries. I am glad that Micra is one of our therapy options."
"Micra is the only leadless pacing system available for clinical practice. Micra reduces the complication rate for our patients."
"Micra has revolutionized the field of cardiac pacing by miniaturizing a pacemaker and rendering it entirely intracardiac."
"My patients appreciate that compared to conventional pacemakers, Micra provides greater post-procedure mobility."
"For us, Micra is definitely the best innovation in cardiac pacing in this past decade. With Micra AV, the indicated patient population has expanded."
"Micra is a game changer in the world of pacing. A marvelous innovation — a pacemaker, the size of a pill being able to sense in the atrium and pace in the ventricle."
Access interactive courses, videos, and educational resources to expand your learning on Micra.
Check out our physician brochure featuring device specifications, algorithm details, clinical evidence, and more.
Visit our physician webpage to learn more about our portfolio of Micra leadless pacemakers.
The single chamber Micra transcatheter pacing system is being described herein as Micra VR in order to distinguish it from the dual chamber (VDD) Micra AV product. When information in this document relates to both Micra AV and VR, “Micra transcatheter pacing systems” is used to represent the portfolio of devices.
Akatsu, Susumu. 100,000 Micra Patients Implanted. May 2021. Medtronic data on file.